Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by Solid1on Feb 23, 2023 10:06am
311 Views
Post# 35300559

NDA - ANDA

NDA - ANDA
Pidduck is talking about two approval processes here ? 
Or am I misunderstanding something ? 

David Pidduck
Yes. We thought it was important to update investors on some of the work that we've done. I think, MediPharm is probably a global leader in the characterization of pharmaceutical CBD. And with that, and with our Drug Establishment License, and with our drug master file with the U.S. FDA, it gives us an opportunity to supply API to pharmaceutical companies. So in Q3, we provided API for new novel drug applications, which are very long by nature, as well as abbreviated new drug application. And abbreviated new drug application is basically a generic application.
So our pharmaceutical partner is targeting current pharmaceutical drugs with cannabinoids and API, and they're filing a generic for that. We are being a little bit restrictive in some of the information that we're doing. There's a competitive advantage of not fully disclosing as our pharmaceutical partner would prefer that we don't get into too much detail. But as the file makes its way through the process, we will be able to continue to update all of our stakeholders.

<< Previous
Bullboard Posts
Next >>